CONSHOHOCKEN, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced the company will participate in a fireside chat at the H.C. Wainwright 8th Annual MASH Virtual Investor Conference at 2:00 P.M. ET on Monday, Oct. 7, 2024.
The fireside chat will be webcast live and may be accessed here or by visiting Madrigal’s website’s Investor Relations Events page. A replay of the webcast will be available after the event.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of NASH. For more information, visit www.madrigalpharma.com.
Investor Contact
Tina Ventura, IR@madrigalpharma.com
Media Contact
Christopher Frates, media@madrigalpharma.com
LANCASTER, Calif., May 15, 2025 /PRNewswire/ -- Legacy Education Inc. (NYSE American: LGCY), a leading…
Conference call and webcast rescheduled for 8:30 a.m. Eastern Time on Monday, May 19 NEW…
SAN FRANCISCO, May 15, 2025 /PRNewswire/ -- MediKarma, a digital health company specializing in AI-powered…
BOSTON, May 15, 2025 /PRNewswire/ -- Dentegrate AI is revolutionizing dental practice growth, with over…
Clinical trial advances for INSTASYL siRNA lead product candidate PH-762 4th Cohort enrolling and treating…
Successfully Completes Capital Structure Reset with Series A Preferred ConversionCharlotte, North Carolina--(Newsfile Corp. - May…
![](data:image/svg+xml;charset=utf-8,<svg height="32px" width="32px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="1px" width="1px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
